InnovaDx

08/03/2022

Wishing all the women around the world a very Happy International Women’s Day! More power to you all❤️

11/12/2021

"Showing that you are free from COVID-19 at the time of an unmasked gathering is something we should be able to normalize"

Since this virus and all of its variants can spread without symptoms, we need to be sure we’re not shedding the virus at gatherings.

11/12/2021

New product launched: Saliva Covid-19 Antigen test kit. Welcome to contact us for more details.

Email: info@innovadx.co.uk
__________________________________________

05/08/2021

21/06/2021

The COVID-19 vaccine, just like any other vaccine, works by teaching your immune system how to defend itself against attack from the virus: nhs.uk/CovidVaccine

27/04/2021

Fluorescent Immunoassays (FIA)
Fluorescent Immunoassays are simply a different type of immunoassay. The key variable is the biochemical technique used for detecting the binding of the “detection” antibody and the analyte molecule. The advantages of a Fluorescent detection system have been known for many years. These include higher sensitivity detection of the analyte, simplified reagents and simpler assay designs. Several breakthroughs have occurred over the past few years that have enabled the implementation of a fluorescent based immunoassay system at the point of care.

A modern fluorescent based immunoassay uses as the detection reagent a fluorescent compound which absorbs light or energy (excitation energy) at a specific wavelength and then emits light or energy at a different wavelength. The difference between the wavelength of the excitation light and the emission light is called the Stokes shift. The greater the shift or difference in the wavelength the less interference there will be by having the excitation light detected as part of the emission light. Recently a number of technical improvements have occurred that has enabled the implementation of a high sensitivity immunoassay system. These include the availability of narrow wavelength low cost light sources, newer more stable fluorophores that have very wide Stokes shifts, stable solid state light detectors and microprocessors to process and analyze the data from each test.

When a fluorescent detection system is linked to a lateral flow assay and matched with a powerful yet low cost analyzer like the Innovadx DX-1 and DX-3, the result is improved assay performance, the opportunity for walk away testing along with the elimination of misinterpretation often associated with visually-read point-of-care assays.

24/04/2021

Twice weekly rapid testing to be available to everyone in England

Everyone in England will be able to access free, regular, rapid coronavirus (COVID-19) testing from 9 April, the government has announced.

18/04/2021

Pioneering New Diagnostics: Addressing Challenges and Implications for Point-of-Care Testing in African Settings

Pioneering New Diagnostics: Addressing Challenges and Implications for Point-of-Care Testing in African Settings Point-of-Care Testing: Why is it important? Imagine yourself in a city at the centre of one of the world’s deadliest disease outbreaks. You watch as your friends and relatives are struc...

12/04/2021

Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19

Kile Green1, Sara Graziadio2, Philip Turner3,4, Thomas Fanshawe3,4, Joy Allen1 On behalf of the Oxford COVID-19 Evidence Service Team Centre

10/04/2021

Introducing our high sensitivity InnovaDX DX-1 Platform. A next generation point-of-care diagnostic system, that combines a small, portable Instrument; advanced method of Time-resolved Fluorescence Immunoassay (TRFIA); simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems, for the in-vitro quantitative detection of bio-markers for Diabetes Mellitus, Inflammation, Cardiovascular Diseases, Hormone, Gastric Diseases, Renal Diseases, Tumor, etc

09/04/2021

POCT in the ED - relevant clinical and economical advantages

In the ED, 25 % of patients with angina pectoris with suspected AMI are wrongly diagnosed (no cardiac involvement). As a result, the patient risks are increased...

08/04/2021

Potential of Next-generation POCT in Infectious Disease Rapid Test

Potential of Next-generation POCT in Infectious Disease Rapid Test Potential of Next-generation POCT in Infectious Disease Rapid Test Author: Shimetani N Date: 20 October 2017 Abstract: Real-time test results are necessary for early diagnosis and in determining treatment orientation in medical pract...